Biparatopic Bispecifics from ATX-CLC Transgenic Mice & mAbForge Multi Discovery

• Biparatopic antibodies, which engage two non-overlapping epitopes on a single target, offer distinct mechanistic advantages including enhanced avidity, receptor clustering, and resistance mitigation, but conventional discovery approaches often struggle to generate pairs that are both functionally optimized and readily manufacturable
• Alloy Therapeutics has developed the ATX-CLC transgenic mouse platform, a suite of common light chain mice that enable monoclonal antibodies to be mixed and matched across a range of bispecific formats while preserving native Fab architecture, and the mAbForge Multi high-throughput screening workflow for rapid pairing and functional triage
• Together, these platforms support the discovery of fully manufacturable biparatopic and bispecific candidates, including T-cell engager formats, without compromising binding affinity or developability
• We highlight a biparatopic case study spanning discovery through format selection, demonstrating how our platforms accelerate development of next-generation multispecific biologics across diverse therapeutic areas

Speakers:

Heather Cooke

Senior Director, Protein Sciences & Bispecific Antibody Engineering

Alloy Therapeutics